Ptc Therapeutics (PTCT) Other Non-Current Liabilities (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Other Non-Current Liabilities of $14.5 million for Q2 2026, up 85.34% year-over-year from $7.8 million in Q2 2025, and up 5.82% quarter-over-quarter from $13.7 million in Q1 2026.
Ptc Therapeutics (PTCT) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $14.5 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 85.34% year-over-year to $14.5 million; the TTM figure through Jun 2026 stood at $14.5 million (up 85.34% YoY), while the FY2025 annual figure was $13.7 million, down 36.04% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $14.5 million, up from $13.7 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $228.2 million in Q1 2022, with the low at $2.6 million in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $36.2 million (2024), against an average of $67.4 million.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities plunged 88.28% in 2025, then surged 85.34% in 2026.
- Ptc Therapeutics' Other Non-Current Liabilities stood at $164.0 million in 2022, then tumbled by 77.87% to $36.3 million in 2023, then slumped by 40.98% to $21.4 million in 2024, then tumbled by 36.04% to $13.7 million in 2025, then increased by 5.82% to $14.5 million in 2026.
- Business Quant data shows PTCT's Other Non-Current Liabilities at $14.5 million in Q2 2026, $13.7 million in Q1 2026, and $13.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.50 Mn |
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 13.70 Mn |
| Sep 30, 2025 | 2.58 Mn |
| Jun 30, 2025 | 7.82 Mn |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 141,000.00 |
| Mar 31, 2024 | 36.20 Mn |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 141,000.00 |
| Jun 30, 2023 | 141,000.00 |
| Mar 31, 2023 | 141,000.00 |
| Dec 31, 2022 | 164.00 Mn |
| Sep 30, 2022 | 4.69 Mn |
| Jun 30, 2022 | 163.00 Mn |
| Mar 31, 2022 | 228.20 Mn |
| Dec 31, 2021 | 239.90 Mn |
| Sep 30, 2021 | 252.00 Mn |
| Jun 30, 2021 | 1.39 Mn |